Etanercept News and Research

RSS

Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.

Etanercept and chemo might reduce fatigue in cancer patients

Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.

3 May 2006

Protein levels predict bone marrow transplant survival

Researchers say that protein levels can predict which bone marrow transplant patients are likely develop a deadly complication a week after the procedure and well before any symptoms occur.

19 Feb 2006

Protein level predicts who will develop graft vs. host disease after marrow transplant

Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

17 Feb 2006

Potential oral drug for rheumatoid arthritis

A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.

26 Sep 2005

New treatment approach for severe asthma

Researchers have uncovered a potentially new treatment approach for severe asthma, by blocking a powerful immune system chemical, present in large amounts in patients with the severe form of the disease, a small study in Thorax reveals.

26 Sep 2005

New treatment approach for severe asthma

20 Sep 2005

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

15 Aug 2005

Biologic treatments to treat the physical symptoms of psoriasis

More than 4.5 million adults in the United States have been diagnosed with psoriasis and 21 percent of those have moderate to severe psoriasis. This chronic condition, characterized by thick, red, scaly plaques that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

21 Jul 2005

Arthritis patients still suffer as drugs guidelines are ignored

Access to drugs whose use was approved by the UK's National Institute for Health and Clinical Excellence (NICE) three years ago is still being denied to patients with severe rheumatoid arthritis.

7 Jun 2005

Experts call for improved access to treatment for psoriatic arthritis

MPs gathered at the House of Commons on Tuesday (April 5th) as experts and patient groups urged members of parliament to lobby for improved access to treatment for patients with psoriatic arthritis, a little known and poorly understood condition in which patients experience symptoms of both psoriasis and arthritis.

6 Apr 2005

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.

3 Apr 2005

Wyeth responds to patent lawsuit ruling

Wyeth responded to the ruling today by the U.S. Court of Appeals for the Federal Circuit in the case of Israel Bio-Engineering Project v. Amgen, Inc.

16 Mar 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

Enbrel to treat rheumatoid arthritis approved in Japan

Wyeth K.K. and Takeda Pharmaceutical Company Limited (Takeda) have announced that Enbrel (etanercept) has been approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to existing therapies.

27 Jan 2005

Trial of Etanercept for Wegners's disease shows no benefit against the autoimmune condition

A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.

26 Jan 2005

Pneumococcal vaccinations help protect patients with rheumatoid arthritis against serious pneumococcal infections of the lungs, brain, blood, and ears

Rheumatoid arthritis patients have an approximately two-fold increased morbidity and mortality in infections compared to a population without the disease.

18 Oct 2004

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.

7 Aug 2004

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health.

5 Aug 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

Enbrel therapy allowed more rheumatoid arthritis patients to achieve clinical remission

New results from TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) demonstrated that Enbrel® (etanercept) therapy allowed significantly more rheumatoid arthritis (RA) patients to achieve clinical remission at two years compared to patients treated with methotrexate alone.

11 Jun 2004

Etanercept News and Research

Etanercept and chemo might reduce fatigue in cancer patients

Protein levels predict bone marrow transplant survival

Protein level predicts who will develop graft vs. host disease after marrow transplant

Potential oral drug for rheumatoid arthritis

New treatment approach for severe asthma

New treatment approach for severe asthma

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

Biologic treatments to treat the physical symptoms of psoriasis

Arthritis patients still suffer as drugs guidelines are ignored

Experts call for improved access to treatment for psoriatic arthritis

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Wyeth responds to patent lawsuit ruling

Biologic therapies are changing the way dermatologists treat psoriasis

Enbrel to treat rheumatoid arthritis approved in Japan

Trial of Etanercept for Wegners's disease shows no benefit against the autoimmune condition

Pneumococcal vaccinations help protect patients with rheumatoid arthritis against serious pneumococcal infections of the lungs, brain, blood, and ears

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

Enbrel therapy allowed more rheumatoid arthritis patients to achieve clinical remission

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News